Refractory Non-Hodgkin Lymphoma Clinical Trial
Official title:
A Clinical Study to Evaluate the Efficacy and Safety of Autologous Hematopoietic Stem Cell Transplantation(ASCT) Bridging Chimeric Antigen Receptor T(CART) Cell Therapy in the Treatment of Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT number | NCT04923789 |
Other study ID # | 2020173 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | September 1, 2020 |
Est. completion date | March 1, 2023 |
This is a single center, prospective cohort study to to evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation(ASCT) bridging chimeric antigen receptor T (CART) cell therapy in the treatment of relapsed/refractory B-cell non-Hodgkin's lymphoma.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | March 1, 2023 |
Est. primary completion date | March 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Histologically confirmed B-NHL with extrinsic involvement. 2. Age = 18 years and = 65 years. 3. Measurable disease of at least 15mm(node)/10mm(extranodal) 4. Meet any of the following conditions :1. After 4 courses of standard first-line treatment or 2 courses of treatment with more than two lines, the lesions decreased by less than 50%;2 B-NHL with disease progression after first-line or induction treatment;3. Relapsed B-NHL within 12 months after ASCT;4. After standard chemotherapy or hematopoietic stem cell transplantation, the size of any new lesions or the previously involved site which had achieved complete remission increased by 50% or more. 5. Receive standard autologous hematopoietic stem cell transplantation with CD34+ cells =2*10^6/kg. 6. Estimated survival time =3 months Exclusion Criteria: 1. Having received allogeneic hematopoietic stem cell transplantation previously; 2. HIV-positive; 3. Active hepatitis B or C infection; 4. Previous history of other malignant tumors. Excluded: Patients who had cured basal or squamous cell carcinoma of the skin and carcinoma in situ of the cervix at any time prior to the study; Patients with disease-free survival =5 years who had been cured by surgery only without further treatment for the other tumors listed above can be included in the study. 5. Patients with cardiac insufficiency:ejection fraction (EF) < 30%, NYHA standard, grade II or above 6. Patients with liver and renal insufficiency: Serum Direct Bilirubin (SB) =2mg/ dL (34.2µmol/L), Aspartate Aminotransferase(AST) > 2.5 times the up, Serum Creatinine (SCR) > 2.5mg/ dL (221µmol/L) 7. Female patients who are pregnant, preparing to become pregnant or lactating. 8. The investigator believes that there are other factors that are not suitable for inclusion or affect subjects' participation or completion of the study. |
Country | Name | City | State |
---|---|---|---|
China | The First Affiliated Hospital of Soochow University | Suzhou | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
The First Affiliated Hospital of Soochow University | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free Survival(PFS) | The last follow-up of a surviving patient after ASCT to the date of relapse, disease progression, death, dependent upon which occurred first over a follow-up period of 18 months. | up to 12 months | |
Primary | Overall Survival(OS) | The interval from the time of ASCT to death from any cause or to the last follow-up moment. | up to 12 months | |
Secondary | Duration of Response(DOR) | DOR will be assessed from ASCT to progression,death or last follow-up. | up to 12 months | |
Secondary | Adverse Events(AE) | Number of participants with adverse events. Frequencies of toxicities based on the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 will be tabulated | Measured from start of treatment until 28 days after last treatment. | |
Secondary | Overall Response Rate(ORR) | Number of patients who achieved response after the treatment. | up to 12 months | |
Secondary | Cumulative Recurrence Rate | Cumulative number of patients who recurred after the treatment. | up to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05420493 -
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
|
Phase 1 | |
Completed |
NCT00005803 -
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03233204 -
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Recruiting |
NCT04545762 -
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
|
Phase 1 | |
Active, not recruiting |
NCT03583424 -
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04150913 -
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
|
Phase 2 | |
Active, not recruiting |
NCT03213691 -
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Recruiting |
NCT06026319 -
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
|
Phase 1 | |
Recruiting |
NCT06119685 -
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
|
Phase 1/Phase 2 | |
Recruiting |
NCT05892718 -
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04284774 -
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
|
Phase 2 | |
Recruiting |
NCT04851119 -
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03220035 -
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Terminated |
NCT02420795 -
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03778619 -
MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03213678 -
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Active, not recruiting |
NCT02568553 -
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
|
Phase 1 | |
Active, not recruiting |
NCT03698994 -
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Active, not recruiting |
NCT03213665 -
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Active, not recruiting |
NCT03210662 -
Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|
Phase 2 |